Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.

18:08 EDT 27th March 2015 | BioPortfolio

Summary of "Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome."

To resolve the genetic heterogeneity within pediatric high-risk B-precursor acute lymphoblastic leukemia (ALL), a clinically defined risk group with few known recurring cytogenetic abnormalities and a poor outcome, we performed gene expression profiling (GEP) in a cohort of 207 uniformly treated children with high-risk ALL. Expression profiles were correlated with genome-wide DNA copy number abnormalities and clinical and outcome features. Unsupervised clustering of GEP data revealed eight unique cluster groups within these high-risk ALL patients, two of which were associated with known chromosomal translocations (t(1;19)(TCF3-PBX1) or MLL), and six of which lacked any previously known cytogenetic lesion. One unique cluster was characterized by high expression of distinct outlier genes AGAP1, CCNJ, CHST2/7, CLEC12A/B and PTPRM; ERG DNA deletions; and a 4-year relapse-free survival (RFS) of 94.7+/-5.1%, compared to 63.5+/-3.7% for the cohort (P=0.01). A second cluster, characterized by high expression of BMPR1B, CRLF2, GPR110, MUC4; frequent deletion of EBF1, IKZF1, RAG1-2, and IL3RA-CSF2RA; JAK mutations and CRLF2 rearrangements (P<.0001); and Hispanic ethnicity (P<.001), had a very poor 4-year RFS (21.0+/-9.5%; P<.001). These studies reveal the striking clinical and genetic heterogeneity in high-risk ALL and point to novel genes which may serve as new targets for diagnosis, risk classification, and therapy.


The University of New Mexico Cancer Center and Departments of Pathology, Internal Medicine, Mathematics & Statistics, and Physics & Astronomy, University of New Mexico, Albuquerque, NM;

Journal Details

This article was published in the following journal.

Name: Blood
ISSN: 1528-0020


PubMed Articles [38728 Associated PubMed Articles listed on BioPortfolio]

Clinically defining and managing high-risk pediatric patients with acute lymphoblastic leukemia.

For children with acute lymphoblastic leukemia, the identification of those at higher risk of disease recurrence and modifying therapy based on this risk is a critical component to the provision of op...

CD20 and Outcome of Childhood Precursor B-cell Acute Lymphoblastic Leukemia: A Meta-analysis.

CD20 is a B-cell differentiation antigen that is expressed variably in precursor B-cell acute lymphoblastic leukemia (BCP-ALL). The prognostic significance of CD20 expression in childhood BCP-ALL rema...

Differentiating the levels of risk for muscle dysmorphia among Hungarian male weightlifters: A factor mixture modeling approach.

Muscle dysmorphia (MD) is a body image disturbance characterized by a pathological preoccupation with muscularity. The study aimed to differentiate the levels of risk for MD among weightlifters and to...

Identification and Characterisation of Health Behaviours in 11- to 17-Year-Old Adolescents: A Cluster Analysis Based on the German Health Interview and Examination Survey for Children and Adolescents.

Background: Negative patterns of health behaviour regarding health are developed and solidified internalised in adolescence. In later years, they can lead to diseases which contribute to a high burden...

Impact of free on-site vaccine and/or healthcare workers training on hepatitis B vaccination acceptability in high-risk subjects: A pre-post cluster randomized study.

Despite recommendations for adults at high-risk of HBV infection, HBV vaccine uptake remains low in this population. A pre-post randomised cluster study was conducted to evaluate the impact of on-site...

Clinical Trials [6114 Associated Clinical Trials listed on BioPortfolio]

EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients

Question: In which stage of an EBV-infection is a selective reduction of immunosuppressive medication reasonable to minimize the risk for PTLD, without putting the transplant recipient at...

Natural History of Oro-pharyngeal Cancer Precursors

Oro-pharyngeal cancers can develop from squamous dysplastic precursor lesions, which occur in a subset of common white (leukoplakia), red (erythroplasia), or mixed oro-pharyngeal plaques. ...

Study of Hypothalamic Metabolism in Spontaneous Cluster Headache Attacks

Cluster headache is characterized by unilateral excruciating head pain and autonomic dysfunction. Hypothalamic overactivity was observed in nitrate-induced cluster-headache and in only one...

Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache

This study's hypothesis is the 4mg StatDose sumatriptan is effective for the acute treatment of cluster headache and provides good safety and tolerability across multiple doses of the stud...

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

We will conduct a 12-week, randomized open label study, comparing usual care (UC) antipsychotic treatment (aripiprazole, quetiapine, risperidone) with ziprasidone (ZIP) in children and ado...

Medical and Biotech [MESH] Definitions

Reduction of high-risk choices and adoption of low-risk quantity and frequency alternatives.

Class I human histocompatibility (HLA) antigens encoded by a small cluster of structural genes at the C locus on chromosome 6. They have significantly lower immunogenicity than the HLA-A and -B determinants and are therefore of minor importance in donor/recipient crossmatching. Their primary role is their high-risk association with certain disease manifestations (e.g., spondylarthritis, psoriasis, multiple myeloma).

An organization of insurers or reinsurers through which particular types of risk are shared or pooled. The risk of high loss by a particular insurance company is transferred to the group as a whole (the insurance pool) with premiums, losses, and expenses shared in agreed amounts.

Removal of a drug from the market due to the identification of an intrinsic property of the drug that results in a serious risk to public health.

Any system which allows payors to share some of the financial risk associated with a particular patient population with providers. Providers agree to adhere to fixed fee schedules in exchange for an increase in their payor base and a chance to benefit from cost containment measures. Common risk-sharing methods are prospective payment schedules (PROSPECTIVE PAYMENT SYSTEM), capitation (CAPITATION FEES), diagnosis-related fees (DIAGNOSIS-RELATED GROUPS), and pre-negotiated fees.

Search BioPortfolio:

Relevant Topics

Latest News Clinical Trials Research Drugs Reports Corporate
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

The top 5 most promising drugs (February 2014)
Latest News Clinical Trials Research Drugs Reports Corporate
THE FIVE MOST PROMISING DRUGS LAUNCHED OR RECEIVING APPROVAL February 2014 Drug Disease Company Gazyva™ Chronic lymphocytic leukemia Biogen Idec/Genentech/ F. Hoffman-La Roche ...

Latest News Clinical Trials Research Drugs Reports Corporate
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...


Searches Linking to this Article